Department of Internal Medicine, Eulji General Hospital, Seoul, Korea.
Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
Surgery. 2018 Aug;164(2):312-318. doi: 10.1016/j.surg.2018.03.018. Epub 2018 May 17.
Hereditary medullary thyroid carcinoma can present as a part of multiple endocrine neoplasia syndrome by rearranged during transfection gene mutation. We evaluated the prevalence of rearranged during transfection gene mutation in patients who have medullary thyroid carcinoma and the correlations of genotype with medullary thyroid carcinoma, pheochromocytoma, and hyperparathyroidism according to the revised American Thyroid Association risk level.
A total of 331 patients were diagnosed with medullary thyroid carcinoma, 172 of whom were tested for the rearranged during transfection germline mutation by sequencing of exon 8, 10, 11, and 13-16. These patients were diagnosed during the years 1982-2012 at 2 Korean tertiary hospitals. Patients were analyzed according to the route of diagnosis (screened versus index cases) or the mutational site of rearranged during transfection gene (the American Thyroid Association risk group).
Rearranged during transfection mutation was found in 23.8% of patients tested, showing a decreasing trend with time. The most commonly mutated codon was codon 634 (37.1%), followed by codon 918 (14.3%). rearranged during transfection-positive patients were younger than rearranged during transfection-negative patients, although no other clinicopathologic characteristics differed. Screened cases were younger and had smaller tumors than index cases. Among rearranged during transfection-positive patients, pheochromocytoma manifested in 35.1% and hyperparathyroidism in 7.0%. Notably, pheochromocytoma and hyperparathyroidism emerged at any time after the diagnosis of medullary thyroid carcinoma. The American Thyroid Association risk-group analysis demonstrated that medullary thyroid carcinoma patients in the highest risk group were younger, had larger tumors, and higher disease-specific mortality. Similar results for pheochromocytoma were found, according to the American Thyroid Association risk group, although the results were not significant.
Korean patients who have medullary thyroid carcinoma showed a similar distribution of rearranged during transfection gene mutation with those in Western countries. The American Thyroid Association risk classification was shown to be useful for pheochromocytoma, as well as for medullary thyroid carcinoma. Familial screening for rearranged during transfection mutation and lifelong monitoring for associated pheochromocytoma should be emphasized in hereditary medullary thyroid carcinoma.
遗传性髓样甲状腺癌可通过转染基因重排呈现为多发性内分泌肿瘤综合征的一部分。我们评估了具有髓样甲状腺癌的患者中转录基因重排突变的流行率,并根据修订后的美国甲状腺协会风险水平,研究了基因型与髓样甲状腺癌、嗜铬细胞瘤和甲状旁腺功能亢进之间的相关性。
共有 331 例患者被诊断为髓样甲状腺癌,其中 172 例通过对外显子 8、10、11 和 13-16 进行测序来检测转录基因的种系突变。这些患者于 1982 年至 2012 年在韩国的两家三级医院被诊断。根据诊断途径(筛查病例与首发病例)或转录基因突变位点(美国甲状腺协会风险组)对患者进行分析。
在接受检测的患者中,发现转录基因突变占 23.8%,且呈随时间下降的趋势。最常见的突变密码子是 634 密码子(37.1%),其次是 918 密码子(14.3%)。转录基因阳性患者比转录基因阴性患者年轻,尽管其他临床病理特征无差异。筛查病例比首发病例年轻,肿瘤更小。在转录基因阳性患者中,嗜铬细胞瘤表现为 35.1%,甲状旁腺功能亢进为 7.0%。值得注意的是,嗜铬细胞瘤和甲状旁腺功能亢进在髓样甲状腺癌诊断后任何时间均可出现。美国甲状腺协会风险组分析表明,最高风险组的髓样甲状腺癌患者更年轻,肿瘤更大,疾病特异性死亡率更高。根据美国甲状腺协会风险组,嗜铬细胞瘤也有类似的结果,尽管结果不显著。
韩国的髓样甲状腺癌患者与西方患者的转录基因突变分布相似。美国甲状腺协会风险分类对嗜铬细胞瘤和髓样甲状腺癌都很有用。在遗传性髓样甲状腺癌中,应强调对转录基因突变的家族筛查和对相关嗜铬细胞瘤的终身监测。